MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver

Its close relationship with prognosis of the patients

Suguru Yonezawa, Kazunobu Sueyoshi, Mitsuharu Nomoto, Hiroshi Kitamura, Kohji Nagata, Yoshiko Arimura, Sadao Tanaka, Michael A Hollingsworth, Bader Siddiki, Young S. Kim, Eiichi Sato

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

We have previously reported that MUC2 apomucin was highly expressed in noninvasive tumors of the pancreas (intraductal papillary tumor [IdPT]) and liver (bile duct cystadenocarcinoma [BdCC]), which show more favorable outcomes than invasive carcinomas. In contrast, MUC2 was rarely expressed in invasive carcinomas of the pancreas (invasive ductal carcinoma [IDC]) and the liver (invasive cholangiocarcinoma [ICC]). In the present study, we examined localization of MUC2 messenger RNA (MUC2 mRNA) by using a complementary DNA (cDNA) probe for the MUC2 tandem repeat for in situ hybridization (pHAM1). Localization of MUC2 apomucin was determined by using an antibody directed against MUC2 apomucin (anti-MRP) for immunohistochemistry study. Eleven IdPTs and 10 IDC2 of the pancreas, and 8 BdCC and 8 ICCs of the liver were examined. Nine (82%) of 11 IdPTs showed positive expression of MUC2 mRNA in the neoplastic cells, whereas none (0%) of the IDCs showed expression of MUC2 mRNA. Six (75%) of the 8 BdCCs showed positive expression of MUC2 mRNA in the neoplastic cells, whereas none (0%) of the 8 ICCs showed expression of MUC2 mRNA. The localization of MUC2 mRNA and that of MUC2 apomucin usually coincided, although a few cases (1 IDC, 1 BdCC, and 1 ICC) showed focal expression of MUC2 apomucin despite the absence of detectable MUC2 mRNA. These results indicate that the expression of MUC2 apomucin in IdPTs and BdCCs correlates with expression of MUC2 mRNA. In both patient groups with pancreatic tumors and hepatic tumors, patients with positive MUC2 mRNA expression in the tumors showed significantly better survival than those with negative MUC2 mRNA expression in the tumors. The production of MUC2, an abundant extracellular mucin, by most IdPTs and BdCCs may be correlated with tumors that display lower levels of invasion and metastasis.

Original languageEnglish (US)
Pages (from-to)344-352
Number of pages9
JournalHuman Pathology
Volume28
Issue number3
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Pancreas
Gene Expression
Messenger RNA
Liver
Cystadenocarcinoma
Neoplasms
Pancreatic Ductal Carcinoma
Bile Ducts
Cholangiocarcinoma
Ductal Carcinoma
Tandem Repeat Sequences
DNA Probes
Mucins
In Situ Hybridization
apomucin
Complementary DNA
Immunohistochemistry
Neoplasm Metastasis
Carcinoma
Survival

Keywords

  • MUC2 apomucin
  • MUC2 messenger RNA
  • in situ hybridization
  • liver
  • pancreas

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver : Its close relationship with prognosis of the patients. / Yonezawa, Suguru; Sueyoshi, Kazunobu; Nomoto, Mitsuharu; Kitamura, Hiroshi; Nagata, Kohji; Arimura, Yoshiko; Tanaka, Sadao; Hollingsworth, Michael A; Siddiki, Bader; Kim, Young S.; Sato, Eiichi.

In: Human Pathology, Vol. 28, No. 3, 01.01.1997, p. 344-352.

Research output: Contribution to journalArticle

Yonezawa, Suguru ; Sueyoshi, Kazunobu ; Nomoto, Mitsuharu ; Kitamura, Hiroshi ; Nagata, Kohji ; Arimura, Yoshiko ; Tanaka, Sadao ; Hollingsworth, Michael A ; Siddiki, Bader ; Kim, Young S. ; Sato, Eiichi. / MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver : Its close relationship with prognosis of the patients. In: Human Pathology. 1997 ; Vol. 28, No. 3. pp. 344-352.
@article{bcb5666a44104e68bd19fe929eb9b4d2,
title = "MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: Its close relationship with prognosis of the patients",
abstract = "We have previously reported that MUC2 apomucin was highly expressed in noninvasive tumors of the pancreas (intraductal papillary tumor [IdPT]) and liver (bile duct cystadenocarcinoma [BdCC]), which show more favorable outcomes than invasive carcinomas. In contrast, MUC2 was rarely expressed in invasive carcinomas of the pancreas (invasive ductal carcinoma [IDC]) and the liver (invasive cholangiocarcinoma [ICC]). In the present study, we examined localization of MUC2 messenger RNA (MUC2 mRNA) by using a complementary DNA (cDNA) probe for the MUC2 tandem repeat for in situ hybridization (pHAM1). Localization of MUC2 apomucin was determined by using an antibody directed against MUC2 apomucin (anti-MRP) for immunohistochemistry study. Eleven IdPTs and 10 IDC2 of the pancreas, and 8 BdCC and 8 ICCs of the liver were examined. Nine (82{\%}) of 11 IdPTs showed positive expression of MUC2 mRNA in the neoplastic cells, whereas none (0{\%}) of the IDCs showed expression of MUC2 mRNA. Six (75{\%}) of the 8 BdCCs showed positive expression of MUC2 mRNA in the neoplastic cells, whereas none (0{\%}) of the 8 ICCs showed expression of MUC2 mRNA. The localization of MUC2 mRNA and that of MUC2 apomucin usually coincided, although a few cases (1 IDC, 1 BdCC, and 1 ICC) showed focal expression of MUC2 apomucin despite the absence of detectable MUC2 mRNA. These results indicate that the expression of MUC2 apomucin in IdPTs and BdCCs correlates with expression of MUC2 mRNA. In both patient groups with pancreatic tumors and hepatic tumors, patients with positive MUC2 mRNA expression in the tumors showed significantly better survival than those with negative MUC2 mRNA expression in the tumors. The production of MUC2, an abundant extracellular mucin, by most IdPTs and BdCCs may be correlated with tumors that display lower levels of invasion and metastasis.",
keywords = "MUC2 apomucin, MUC2 messenger RNA, in situ hybridization, liver, pancreas",
author = "Suguru Yonezawa and Kazunobu Sueyoshi and Mitsuharu Nomoto and Hiroshi Kitamura and Kohji Nagata and Yoshiko Arimura and Sadao Tanaka and Hollingsworth, {Michael A} and Bader Siddiki and Kim, {Young S.} and Eiichi Sato",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0046-8177(97)90134-9",
language = "English (US)",
volume = "28",
pages = "344--352",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver

T2 - Its close relationship with prognosis of the patients

AU - Yonezawa, Suguru

AU - Sueyoshi, Kazunobu

AU - Nomoto, Mitsuharu

AU - Kitamura, Hiroshi

AU - Nagata, Kohji

AU - Arimura, Yoshiko

AU - Tanaka, Sadao

AU - Hollingsworth, Michael A

AU - Siddiki, Bader

AU - Kim, Young S.

AU - Sato, Eiichi

PY - 1997/1/1

Y1 - 1997/1/1

N2 - We have previously reported that MUC2 apomucin was highly expressed in noninvasive tumors of the pancreas (intraductal papillary tumor [IdPT]) and liver (bile duct cystadenocarcinoma [BdCC]), which show more favorable outcomes than invasive carcinomas. In contrast, MUC2 was rarely expressed in invasive carcinomas of the pancreas (invasive ductal carcinoma [IDC]) and the liver (invasive cholangiocarcinoma [ICC]). In the present study, we examined localization of MUC2 messenger RNA (MUC2 mRNA) by using a complementary DNA (cDNA) probe for the MUC2 tandem repeat for in situ hybridization (pHAM1). Localization of MUC2 apomucin was determined by using an antibody directed against MUC2 apomucin (anti-MRP) for immunohistochemistry study. Eleven IdPTs and 10 IDC2 of the pancreas, and 8 BdCC and 8 ICCs of the liver were examined. Nine (82%) of 11 IdPTs showed positive expression of MUC2 mRNA in the neoplastic cells, whereas none (0%) of the IDCs showed expression of MUC2 mRNA. Six (75%) of the 8 BdCCs showed positive expression of MUC2 mRNA in the neoplastic cells, whereas none (0%) of the 8 ICCs showed expression of MUC2 mRNA. The localization of MUC2 mRNA and that of MUC2 apomucin usually coincided, although a few cases (1 IDC, 1 BdCC, and 1 ICC) showed focal expression of MUC2 apomucin despite the absence of detectable MUC2 mRNA. These results indicate that the expression of MUC2 apomucin in IdPTs and BdCCs correlates with expression of MUC2 mRNA. In both patient groups with pancreatic tumors and hepatic tumors, patients with positive MUC2 mRNA expression in the tumors showed significantly better survival than those with negative MUC2 mRNA expression in the tumors. The production of MUC2, an abundant extracellular mucin, by most IdPTs and BdCCs may be correlated with tumors that display lower levels of invasion and metastasis.

AB - We have previously reported that MUC2 apomucin was highly expressed in noninvasive tumors of the pancreas (intraductal papillary tumor [IdPT]) and liver (bile duct cystadenocarcinoma [BdCC]), which show more favorable outcomes than invasive carcinomas. In contrast, MUC2 was rarely expressed in invasive carcinomas of the pancreas (invasive ductal carcinoma [IDC]) and the liver (invasive cholangiocarcinoma [ICC]). In the present study, we examined localization of MUC2 messenger RNA (MUC2 mRNA) by using a complementary DNA (cDNA) probe for the MUC2 tandem repeat for in situ hybridization (pHAM1). Localization of MUC2 apomucin was determined by using an antibody directed against MUC2 apomucin (anti-MRP) for immunohistochemistry study. Eleven IdPTs and 10 IDC2 of the pancreas, and 8 BdCC and 8 ICCs of the liver were examined. Nine (82%) of 11 IdPTs showed positive expression of MUC2 mRNA in the neoplastic cells, whereas none (0%) of the IDCs showed expression of MUC2 mRNA. Six (75%) of the 8 BdCCs showed positive expression of MUC2 mRNA in the neoplastic cells, whereas none (0%) of the 8 ICCs showed expression of MUC2 mRNA. The localization of MUC2 mRNA and that of MUC2 apomucin usually coincided, although a few cases (1 IDC, 1 BdCC, and 1 ICC) showed focal expression of MUC2 apomucin despite the absence of detectable MUC2 mRNA. These results indicate that the expression of MUC2 apomucin in IdPTs and BdCCs correlates with expression of MUC2 mRNA. In both patient groups with pancreatic tumors and hepatic tumors, patients with positive MUC2 mRNA expression in the tumors showed significantly better survival than those with negative MUC2 mRNA expression in the tumors. The production of MUC2, an abundant extracellular mucin, by most IdPTs and BdCCs may be correlated with tumors that display lower levels of invasion and metastasis.

KW - MUC2 apomucin

KW - MUC2 messenger RNA

KW - in situ hybridization

KW - liver

KW - pancreas

UR - http://www.scopus.com/inward/record.url?scp=12644267300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12644267300&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(97)90134-9

DO - 10.1016/S0046-8177(97)90134-9

M3 - Article

VL - 28

SP - 344

EP - 352

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 3

ER -